A New Antimicrobial Lock Solution to Prevent Catheter-Related Bloodstream Infections

In a randomized, controlled trial, taurolidine/heparin versus heparin lock solution was associated with significantly fewer CRBSIs in patients receiving hemodialysis.

Catheter-related bloodstream infections (CRBSIs) represent a common complication of central venous catheters (CVCs) for hemodialysis, with notable morbidity and mortality. Taurolidine is a novel taurine-derived, broad-spectrum antimicrobial compound with a unique mechanism of action. In a randomized trial, researchers at 70 U.S. centers have now assessed prevention of CRBSIs with catheter lock solutions using 13.5 mg/ml taurolidine plus 1000 unit/ml heparin (T/H) versus standard 1000 unit/ml heparin (H) in 795 patients receiving chronic hemodialysis with CVCs. The primary endpoint was time to CRBSI.

After the first 28 CRBSI cases were identified, an interim analysis found that 6 (2%) of the T/H group as compared with 22 (7%) of the H group h…

Reviewing Author

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health

A New Antimicrobial Lock Solution to Prevent Catheter-Related Bloodstream Infections

Topics

Reviewing Author